However, recent studies identified that measuring cognitive decline in the domain of episodic memory is a powerful tool to study AD progression in DS, as significant changes in episodic memory scores were observed in association with higher tau burden [34] and PET measures of neurodegeneration [58]. This evidence concerns the gene MAPT and Dravet syndrome.